share_log

冠昊生物(300238.SZ):核心业务为材料、药业、细胞三大业务板块

Guanhao Biology (300238.SZ): The core business is the three major business segments of materials, pharmaceuticals, and cells

Gelonghui Finance ·  May 8 16:20

Gelonghui, May 8 | Guanhao Biology (300238.SZ) said on the investor interactive platform that the company's core business is the three major business segments: materials, pharmaceuticals, and cells. The main products in the field of materials include biotype dural (spine) membrane patches, B-type cerebral (spine) membrane patches, thoracic surgical repair films, sterile biological wound protection films, and Ario breast patches, which can be widely used in neurosurgery, thoracic surgery, dermatology, orthopedics, plastic surgery, etc. Benvermide, the main product in the pharmaceutical industry, can treat inflammatory and autoimmune diseases such as psoriasis and atopic dermatitis. The cell field mainly includes cell storage, cellular cartilage therapy, etc.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment